Silence Therapeutics Share Price (SLN)

56.50 -1.40 (-2.42%) delayed: 12:55PM GMT
Bid price 55.20 Open price 58.00
Ask price 57.80 Prev close 56.50
High price 60.50 Spread 4.50%
Low price 54.41 Volume 166,747

Register now for FREE live Silence Therapeutics share prices, Silence Therapeutics stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Silence Therapeutics Level 2 Data, indepth research tools and investor commentary for Silence Therapeutics (SLN) and other London Stock Exchange equities.

Silence Therapeutics Share Price Chart

Advanced Charts >>

Register now for FREE Silence Therapeutics share price charts

Silence Therapeutics Share Price Information

Name Silence Therapeutics Epic SLN
Sector Pharmaceuticals & Biotechnology ISIN GB00B9GTXM62
Activites Silence Therapeutics plc (formerly SR Pharma plc, formerly Stanford Rook Holdings plc) develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. Index n/a

Silence Therapeutics Key Numbers

Latest Share Price (p) 56.50 Net Gearing (%) -72.88
Market Capitalisation (£m) 41.15 Gross Gearing (%) 4.83
Shares in issue (m) 71.07 Debt Ratio 0.00
P/E Ratio -25.17 Debt-to-Equity Ratio 0.00
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.05
Dividend Yield (%) 0.00 Price to book value 0.79
Dividend cover (x) 0.00 ROCE (%) -7.22
Earning per share (p) -2.30 EPS Growth (%) 80.99
52 week high / low 206.00 / 57.90 DPS Growth (%) n/a

Silence Therapeutics Director Deals

Dec.Date Type Director Pos No. of Shares
03/08/2017 BUY Alistair Gray NED 3,848
31/07/2017 BUY Dr Andrew Richards CH 7,000
18/04/2016 BUY Ali Mortazavi RES 160,000
18/04/2016 BUY Dr Stephen Parker NED 6,478
28/11/2012 BUY Ali Mortazavi RES 2,400,000

More Silence Therapeutics Director Deals >>

Silence Therapeutics Company News

07:48 10/12/2018

Silence Therapeutics agrees settlement, licencing deal with Alnylam Pharmaceuticals

RNA-focused pharmaceutical company Silence Therapeutics said it had reached a settlement and license agreement with Alnylam Pharmaceuticals. Alnylam would license patents from Silence and pay it a tiered royalty on net sales of Onpattro in the European Union, ranging from 0.33%-to-1.00% through...

07:00 10/12/2018

Settlement and License Agreement with Alnylam

RNS Number : 8956J Silence Therapeutics PLC 10 December 2018     Silence Therapeutics, PLC enters into a Settlement and License Agreement with Alnylam Pharmaceuticals   All legal proceedings, in all jurisdictions, between Silence and Alnylam are withdrawn with...

More Silence Therapeutics Company News >>

Register now for FREE Silence Therapeutics company news

Silence Therapeutics Share Price Discussions

more than 1 year ago

Silence Therapeutics (SLN)

SILENCE THERAPEUTICS plc ("Silence Therapeutics" or "the Group") INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2007 London, UK, 28 September 2007 - Silence Therapeutics plc (London LSE: SLN)...

more than 1 year ago

Silence Therapeutics (SLN)

Cant find original Should be good next week

Register now for FREE Silence Therapeutics share price discussions